Inozyme Pharma Inc

NASDAQ:INZYUnited States

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.

Contact Information

Headquarters

321 SUMMER STREET, SUITE 400BOSTON, MA, United States 02210

Phone

857-330-4340

Fax

302-655-5049

Executives

Chairman of the Board, Chief Executive Officer

Douglas Treco

Chief Financial Officer, Corporate Secretary

Sanjay Subramanian

Chief Operations Officer

Matthew Winton

Director

Axel Bolte

Director

Erik Harris